Abstract Angiotensin type 1 receptor blockers (ARBs) have been shown to be neuroprotective and neurorestorative in experimental stroke. The mechanisms proposed include anti-inflammatory, antiapoptotic effects, as well as stimulation of endogenous trophic factors leading to angiogenesis and neuroplasticity. We aimed to investigate the involvement of the neurotrophin, brain-derived neurotrophic factor (BDNF), in ARB-mediated functional recovery after stroke. To achieve this aim, Wistar rats received bilateral intracerebroventricular (ICV) injections of short hairpin RNA (shRNA) lentiviral particles or nontargeting control (NTC) vector, to knock down BDNF in both hemispheres. After 14 days, rats were subjected to 90-min middle cerebral artery occlusion (MCAO) and received the ARB, candesartan, 1 mg/kg, or saline IV at reperfusion (one dose), then followed for another 14 days using a battery of behavioral tests. BDNF protein expression was successfully reduced by about 70 % in both hemispheres at 14 days after bilateral shRNA lentiviral particle injection. The NTC group that received candesartan showed better functional outcome as well as increased vascular density and synaptogenesis as compared to saline treatment. BDNF knockdown abrogated the beneficial effects of candesartan on neurobehavioral outcome, vascular density, and synaptogenesis. In conclusion, BDNF is directly involved in candesartanmediated functional recovery, angiogenesis, and synaptogenesis.
Introduction
Angiotensin type 1-receptor blockers (ARBs) have been shown to reduce neurovascular injury and improve recovery after experimental ischemic stroke [1] [2] [3] [4] . The underlying mechanisms are multifaceted and include normalizing cerebral blood flow [2] , restoring endothelial nitric oxide synthase (eNOS) activity, antioxidant, anti-inflammatory, antiapoptotic effects, as well as stimulation of proangiogenic trophic factors [1, [5] [6] [7] [8] [9] [10] . Data from our lab demonstrated that the prorecovery effect induced by a single dose of candesartan was maintained for 7 days after stroke. This was accompanied by a proangiogenic state in both stroked and normal animals [8] . Additionally, we have shown that candesartan treatment was associated with upregulation of brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) in rat brain after stroke, and in cultured human brain endothelial cells [11] [12] [13] .
BDNF is a member of the neurotrophin family that can exert neuroprotective, neuroplastic, neurogenic, and angiogenic effects thus leading to recovery after CNS insults [14, 15] . Lower serum BDNF levels have been associated with increased risk of stroke in humans [16] . Experimentally, BDNF has been shown to be involved in angiogenesis, synaptogenesis, and functional recovery after stroke [17] [18] [19] . ICV injection of collagen-binding BDNF promoted angiogenesis, reduced cell apoptosis, and improved functional recovery after MCAO in rats [20] . Similarly, brain transplantation of human neural stem cells overexpressing BDNF has been shown to stimulate brain angiogenesis and promote functional recovery in a mouse intracerebral hemorrhage model [21] . Synaptophysin is a synaptic protein that is expressed during synapse formation, and therefore considered as a marker of synaptogenesis [22] . Synaptophysin upregulation after experimental stroke coincided with BDNF expression. Moreover, post-stroke IV administration of BDNF increased synaptophysin expression and enhanced motor recovery in rats [18] .
Our work and others have documented the increased expression of BDNF and its receptor, TrkB, with ARB treatment after experimental CNS disorders including stroke [13, [23] [24] [25] . Specifically, studies by Krikov et al. and Ishrat et al. demonstrated an increase in BDNF and TrkB expression with candesartan treatment after experimental stroke [13, 23] . While this suggests an association between candesartan-mediated functional recovery and BDNF/TrkB system, a causal relationship is not yet established. Additionally, we have previously shown that BDNF is directly involved in the proangiogenic effect of candesartan on human brain microvascular endothelial cells but this was done only in vitro [11] . Therefore, it is still not clear whether BDNF is directly involved in the candesartan-mediated proangiogenic state and functional recovery after experimental ischemic stroke in vivo. To test this, we knocked down BDNF in rat brains before stroke induction and candesartan treatment, using short hairpin RNA (shRNA) lentiviral particles. Animals were followed up for 14 days using behavioral tests; then, the brains were collected for vascular density measurement to determine the involvement of BDNF in candesartan-mediated functional recovery and angiogenesis, respectively, after stroke.
Materials and Methods

Animals
All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the Charlie Norwood Veterans Affairs Medical Center. Experiments were performed on 7-8-week-old adult male Wistar rats (200-220 g) that were singly housed with free access to food and water.
In Vivo BDNF Knockdown Intracerebroventricular (ICV) injections were conducted using a stereotaxic instrument under isoflurane anesthesia. Stereotaxic coordinates used were −1 mm anteroposterior, 2 mm lateral, and −3 mm dorsoventral relative to bregma. Five microliters of lentiviral BDNF shRNA (SMARTchoice lentiviral rat Bdnf hCMVTurboGFP shRNA, 1 × 10 8 TU/mL, Dharmacon, # SH0800460210) or nontargeting control vector (NTC) were slowly injected over 5 min into each of the lateral ventricles. Animals were then kept for 14 days to allow for recovery, and viral particle integration into their genome, shRNA expression, and BDNF knockdown. The first set of animals was sacrificed at 14 days to test the degree of knockdown (Fig. 1a) , and a second set was subjected to MCAO, then followed up for another 14 days as described below (Fig. 1b) .
Cerebral Ischemia
Fourteen days after the ICV injection, rats (9-10 weeks old, 280-320 g) were subjected to 90-min middle cerebral artery occlusion (MCAO) as described previously [26] . At the time of reperfusion, animals were randomized to receive either candesartan (1 mg/kg) or saline intravenously (IV). Rats were followed up for another 14 days using neurobehavioral tests and then were euthanized at day 14 post-stroke as previously described [4, 8, 9] . Brains were harvested and fixed in 4 % paraformaldehyde overnight, transferred to 30 % sucrose, then cut into frozen sections using a microtome.
Behavioral Outcome Analysis
Functional outcome was evaluated by a blinded investigator using a battery of behavioral tests on days 1, 4, 7, 10, and 14 after MCAO:
Modified Bederson Test Rats were given a score from 0 to 4 based on their behavior in an open field.
Beam Walk Test Rats' balance on a horizontal beam was observed and scored from 0 to 6.
Paw Grasp Test Rats were held by tail, allowed to grasp a vertical pole and scored from 1 to 3. In these three tests, higher score denotes worse outcome. Detailed description of the tests was provided previously [26] .
Grid Walking Test Rats were placed on a grid composed of 3.8 × 3.8 cm cells, elevated 1 m above the floor. A camera was placed at a 45°angle below the grid to videotape animal movement for 5 min. Two blinded investigators counted the number of forelimb fault steps in addition to the total number of steps. Results were presented as % faulty steps.
Immunohistochemistry
Sections were processed simultaneously as described previously [27] . Primary antibodies were incubated overnight at 4°C at the following dilutions: rabbit anti-laminin (1/ 50; DakoCytomation), anti-synaptophysin (1/50; Abcam), anti-VEGF (1/200; Millipore), anti-NeuN (1/200; Millipore), and anti-GFAP (1/300; Sigma), followed by fluorescent secondary antibodies for 1 h at room temperature. Negative controls were prepared by omitting the primary antibodies. Laminin-stained vascular profiles and VEGF immunofluorescence were quantified using ImageJ software (NIH) in five different fields per section digitized from the ischemic border zone using a ×20 objective lens. Similarly, synaptophysin was quantified in four different fields from both hemispheres using ImageJ software (NIH). Images were taken using Zeiss LSM 510 confocal microscope.
Western Blot Analysis
To confirm BDNF knockdown, brains (whole cerebral hemispheres) collected 14 days after ICV injection were separated Fig. 1 Intracerebroventricular delivery of BDNF shRNA expressing lentiviral particles inhibits BDNF expression. a BDNF shRNA expressing lentiviruses were injected into the lateral ventricles of Wistar rats, and animals were sacrificed after 14 days. Unilateral and bilateral ICV injection achieved about 30 and 70 % reduction in BDNF protein levels, respectively, as assessed by Western blotting. n = 3 per group. b Schematic diagram of the study: animals were subjected to 90-min MCAO after 14 days of bilateral ICV injection and randomized to IV candesartan (1 mg/kg) or saline at reperfusion into left and right sides then homogenized and run on SDS-PAGE as described previously [9] , transferred to nitrocellulose membranes, and probed with anti-BDNF antibody (Santa Cruz). Band optical densities were quantified using ImageJ software (NIH) and divided by the respective loading control (GAPDH) band, then normalized to the right control hemisphere to facilitate the visual comparison of the magnitude of BDNF knockdown from control.
Statistical Analysis
Two-way repeated measure ANOVA was conducted for the behavioral data analysis using SAS 9.4. Post hoc pairwise comparisons between groups over time were performed using a Bonferroni adjustment to the overall alpha level. Differences between groups in immunostaining experiments were examined using two-way ANOVA test followed by Tukey post hoc analysis using GraphPad prism software (5.1). Statistical significance was assessed at an alpha level of 0.05. Results are presented as mean ± SEM.
Results
Short Hairpin RNA Knocks Down BDNF Gene Expression in a Dose-Dependent Manner
We aimed to knock down BDNF in the brain immediately before induction of stroke to assess its involvement in candesartan's effect on stroke outcome. To achieve this, we determined the efficiency of unilateral and bilateral intracerebroventricular (ICV) injection of lentiviruses expressing BDNF shRNA. While unilateral injection achieved only 30 % knockdown of BDNF protein, bilateral injection successfully knocked down BDNF expression by about 70 % after 14 days as assessed by Western blotting (Fig. 1a) . Therefore, we used bilateral ICV injection for the following experiments. Animals with BDNF knockdown did not show differences in weight gain or motor performance compared to those treated with nontargeting control (NTC) vector. Similarly, weight change after stroke was not affected by BDNF knockdown (data not shown). As shown in the schematic diagram (Fig. 1b) , animals were subjected to 90 min-MCAO after 14 days of bilateral ICV injection and randomized to candesartan (1 mg/kg) or saline at reperfusion. This 2 × 2 study design resulted in four treatment groups: BDNF knockdown rats treated with candesartan or saline (cand/KD or sal/KD) and control rats that received NTC vector then candesartan or saline (cand/ NTC or sal/NTC).
Single Dose Candesartan Administration Leads to BDNF-Dependent Long-Term Functional Improvement After Stroke Data from our lab and others have demonstrated the prorecovery effect of ARB treatment on stroke outcome [2, 4, 8, 28] . As previously published [8] , a single dose of candesartan successfully achieved long-term functional improvement up to 14 days after stroke. This improvement was evident as early as day 1 after stroke and was consistently observed in different functional tests in the cand+NTC group as compared to sal+NTC (Fig. 2) . Candesartan has been shown to increase BDNF expression [9] , which is known to play a vital role in functional recovery after stroke [17-19, 29, 30] . Knocking down BDNF abrogated the candesartaninduced functional improvement (Fig. 2) . The effect of knocking down BDNF on functional outcome was observed immediately after stroke and maintained during the whole period of follow-up. However, BDNF knockdown did not further worsen the stroke outcome in the saline-treated animals.
Candesartan Induces a BDNF-Dependent Proangiogenic Response in the Brain
We have previously demonstrated the ability of candesartan to induce a robust proangiogenic response in the brain after experimental stroke [8] . BDNF is a well-established angiogenic factor and was found to mediate a large part of candesartan-induced angiogenesis in vitro [11] . Here, we assessed the role of BDNF in candesartan-induced angiogenesis after stroke in vivo. As expected, a single dose of candesartan induced a robust increase in vascular density in the ischemic border zone at 14 days after stroke (cand/NTC vs sal/NTC). BDNF knockdown rats treated with candesartan (cand/KD) showed less angiogenic response that did not reach statistical significance (Fig. 3) .
Candesartan Regulates VEGF Expression in a BDNF-Dependent Manner
We have previously demonstrated the ability of candesartan to increase VEGF expression after stroke [8, 9] . In addition, VEGF expression has been shown to be regulated by BDNF [31, 32] . It is still unknown whether BDNF regulates VEGF expression in the brain after stroke. Astrocytes and neurons are major sources of VEGF after stroke [33] [34] [35] . At the ischemic border zone, VEGF expression strongly co-localized with Candesartan treatment induced a BDNF-dependent increase in VEGF expression in the ischemic border zone. VEGF expression strongly co-localized with the astrocyte marker, GFAP, including astrocyte end-feet surrounding blood vessels at the ischemic border zone (marked by arrows) (a). VEGF expression also co-localized, to a lesser extent, with and around the neuronal marker, NeuN (marked by arrows-images taken from the ischemic hemisphere of a rat treated with cand/NTC) (c). Data is presented as mean ± SEM; n = 5-7 per group reactive astrocytes, including astrocyte end-feet surrounding blood vessels (Fig. 4a) . In addition, VEGF was co-localized with neurons but to a lesser extent (Fig. 4c) . Consistent with our previous data, candesartan treatment showed a strong trend toward increased VEGF immunoreactivity in the brain sections as compared to saline (cand/NTC vs sal/NTC, p = 0.054, twoway ANOVA). BDNF knockdown blunted candesartaninduced VEGF expression, suggesting a link between BDNF and VEGF upregulation (Fig. 4b) . BDNF knockdown did not affect the basal VEGF expression in saline treated animals.
Candesartan Induces a BDNF-Dependent Synaptogenesis in the Brain
Candesartan has been shown to enhance synaptogenesis after experimental stroke [36] . Moreover, the contralesional hemisphere has been shown to actively remodel after stroke [37] , and angiotensin modulation increases this response [9, 26] . Candesartan administration increased synaptophysin expression in both hemispheres as compared to saline (cand/NTC vs sal/NTC). Candesartan treatment in BDNF knockdown rats did not achieve similar increase in synaptogenesis (Fig. 5 ).
Discussion
Our data demonstrates the involvement of BDNF in ARBmediated long-term recovery after stroke. Additionally, we demonstrated that the candesartan proangiogenic effect is BDNF-dependent in vivo. Furthermore, our data supports the ability of candesartan to induce a BDNF-dependent synaptogenesis. Interestingly, BDNF knockdown by itself did not alter endogenous recovery mechanisms after stroke.
Because of its vital role in cardiovascular [38] and central nervous system [39, 40] development, homozygous (BDNF−/−) knockout animals have limited survival after birth [38] . Heterozygous (BDNF+/−) or TrkB knockout mice are viable but compensatory mechanisms that may occur during neurodevelopment are unknown. The use of shRNA lentiviral particles allows the strategic and localized knockdown of target gene expression in vivo [41] . Lentiviral particles are widely used in central nervous system research since they are retroviruses that integrate in host genome and can infect both dividing and nondividing cells including neurons [42] . Upon integration of lentiviruses into host genome, the carried shRNA is constitutively expressed leading to stable and permanent knockdown of the target gene. As reported previously [43] [44] [45] [46] , we have demonstrated the feasibility of using shRNA-expressing lentiviruses to knock down BDNF in the brain shortly before stroke induction to avoid long-term compensatory mechanisms.
Following ischemic CNS insults, recovery requires a harmonized interplay between different components of the neurovascular unit. Madri et al. demonstrated the essential role of VEGF and BDNF in mediating this interplay [47] . Previously, we have demonstrated the ability of AT1 blockade to increase VEGF and BDNF expression after stroke [9, 12, 13] . This paper was focused on assessing the hypothesis that BDNF is involved in ARB induced recovery after stroke through angiogenesis and neuroplasticity. Therefore, 14 days post-stroke time point was chosen. Our findings demonstrate that AT1 blockade-mediated motor recovery after stroke was blunted with knocking down BDNF. Similarly, AT1 blockademediated angiogenesis and neuroplasticity were negated in BDNF knockdown rats. Collectively, these findings suggest that the AT1 blockade induced prorecovery effect is BDNFdependent. A limitation of the current study is the lack of earlier time point to examine the role of BDNF in candesartanmediated protective effects against early events after stroke such as oxidative stress, inflammation, and apoptosis.
Angiogenesis has been shown to play a vital role in recovery after CNS ischemic insults [48] . We have previously shown that AT1R blockade or AT2R stimulation induce a long-term proangiogenic response in the rat brain after stroke [8, 9, 13, 26] . Additionally, we demonstrated an indispensable role of BDNF in AT1 blockade induced angiogenesis in human cerebromicrovascular endothelial cells (hCMECs) [11] . Our current data demonstrates that this proangiogenic effect is BDNF-dependent in vivo as well. In addition to angiogenesis, recent data demonstrated the importance of neuroplastic changes in the contralateral hemisphere in recovery after stroke [37] . BDNF plays a central role in synaptic plasticity and synaptogenesis [49] , and BDNF knockout mice show reduced synaptophysin expression [50] . IV administration of BDNF after stroke increased synaptophysin expression [18] , while blocking BDNF with specific immunoadhesin chimera (TrkB-IgG) abrogated exercise induced-synaptogenesis. Our results demonstrate the ability of AT1 blockade to increase the extent of synaptogenesis in both the ischemic and contralesional hemispheres in a BDNF-dependent manner.
VEGF is a well-studied angiogenic mediator with established neuroprotective effects [51] . In cancer tissues, VEGF expression was found to be regulated by BDNF [31, 32] . Additionally, the expression of both proteins was demonstrated to be co-regulated [47] . Our data shows increase in VEGF expression with candesartan in NTC-treated animals as compared to those treated with candesartan after BDNF knockdown. This suggests that candesartan-mediated increase in VEGF expression after cerebral ischemia could be, at least, partially mediated through BDNF.
Despite the well-established role of BDNF in recovery after stroke, BDNF knockdown did not worsen stroke outcome in the saline treated animals. Multiple studies have consistently shown that exogenous BDNF administration improve stroke outcome [18, 19, 29, 52, 53] . Paradoxically, one study conducted in BDNF(+/−) mice showed enhanced functional recovery after stroke with decreased brain levels of BDNF [54] . Ploughman et al. assessed the role of endogenous BDNF in rehabilitation induced stroke recovery through knocking down BDNF expression using antisense BDNF oligonucleotide infusion. Their data demonstrated an indispensable role of BDNF in rehabilitation-induced recovery after stroke. Counterintuitively, knocking down BDNF in animals that did not receive rehabilitation did not worsen recovery as compared to vehicle treated animals, which is consistent with our current findings. Collectively, these findings suggest that while therapeutic interventions that are known to increase BDNF expression such as exercise [55, 56] and AT1 blockade [9, 13, 23] , could be dependent on its brain levels, knocking down endogenous brain BDNF expression by itself may not have an effect on stroke recovery.
In conclusion, AT1 blockade with candesartan after stroke induces a BDNF-dependent functional recovery that is associated with both angiogenesis and increased synaptic plasticity. 
